Sinopia Biosciences Inc.

Sinopia Biosciences Inc. is a San Diego-based for-profit corporate entity specializing in computational drug discovery and advanced metabolomics research, with a focus on developing innovative therapeutic solutions using artificial intelligence and machine learning technologies. Registered in SAM.gov since October 2012, the company leverages high-throughput omics technologies and advanced computational platforms to identify novel drug targets, characterize metabolic signatures, and develop potential treatments across various medical domains including oncology, neurodegenerative diseases, and cancer therapeutics.

The company has been awarded multiple federal grants from agencies including the National Cancer Institute, National Institute of General Medical Sciences, National Institute of Dental and Craniofacial Research, and National Institute of Neurological Disorders and Stroke. These grants, ranging from $285,599 to $350,000, have supported projects developing metabolomics-enabled AI/ML platforms for drug discovery, neural network models for compound library characterization, and preclinical assessments of novel compounds targeting conditions such as radiation-induced oral mucositis and Parkinson's disease. Sinopia Biosciences collaborates with research partners like Omix Technologies to advance their computational drug discovery approaches, with a particular emphasis on using metabolomics data to provide more sensitive and predictive insights into drug mechanisms, molecular targets, and potential adverse reactions compared to traditional transcriptomics methods.